Washington State is home to a flourishing biomedical research and innovation hub, and emerging opportunities in bioindustrial manufacturing are turning the state into a biomanufacturing powerhouse.
On Tuesday, August 25, Commissioners Paul Arcangeli and Alexander Titus of the National Security Commission on Emerging Biotechnology (NSCEB) joined Dr. Ali Nouri, senior staff with the Senate Commerce, Science, and Technology Committee, on a visit to Washington State to hear from innovators leading the state’s flourishing health biotech ecosystem and to learn more about how a growing bioindustrial base is reshoring American manufacturing and securing vulnerable supply chains.
“Seattle was recently named one of the top five emerging biotech hubs in the world,” said Marc Cummings, President and CEO of Life Science Washington. “Built on world-class research, collaboration, and leadership in AI and life sciences, the Seattle ecosystem has been at the forefront of American innovation for decades, but today federal funding uncertainty and lower-cost research and clinical trial infrastructure overseas threatens U.S. leadership. As other countries target our leadership in biotechnology, we need to simultaneously streamline our regulatory system and make targeted regional investments to ensure that hubs like Seattle remain competitive.”